I have posted on this INSM message board since 2009 and have seen quite a few ups and downs for Insmed, but IMO the future has never looked brighter. Back then I use to compare Insmed to JAZZ because they both had near identical corporate profiles - to develop drugs for orphan indications - and they both had strong balance sheets which is so incredibly essential for small cap biotechs trying to get to the finish line. JAZZ beat Insmed in the race to gain FDA approvals,, and those shares which sold for 50 cents in 2009 while INSM shareholders were waiting for MMD results now trade for over 125 dollars......but at the same time Insmed has worked their way through the necessary phases to file and hopefully gain it's own approvals, and Insmed has something that JAZZ never did - a drug platform. Rehvdm pointing out that Insmed is in search of a director of new formulations could prove to be key to the company's future,, and my final remark for 2013 is that in a few short years some shares of Insmed may actually be sold by our very own company Historian - at or above his target price. Wouldn't that be cool!!!